Estrella Michelle M, Li Man, Tin Adrienne, Abraham Alison G, Shlipak Michael G, Penugonda Sudhir, Hussain Shehnaz K, Palella Frank J, Wolinsky Steven M, Martinson Jeremy J, Parekh Rulan S, Kao W H Linda
Department of Medicine, Johns Hopkins University School of Medicine.
Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Clin Infect Dis. 2015 Feb 15;60(4):646-52. doi: 10.1093/cid/ciu765. Epub 2014 Oct 3.
Existing data suggest that human immunodeficiency virus (HIV)-infected African Americans carrying 2 copies of the APOL1 risk alleles have greater risk of kidney disease than noncarriers. We sought to determine whether HIV RNA suppression mitigates APOL1-related kidney function decline among African Americans enrolled in the Multicenter AIDS Cohort Study.
We genotyped HIV-infected men for the G1 and G2 risk alleles and ancestry informative markers. Mixed-effects models were used to estimate the annual rate of estimated glomerular filtration rate (eGFR) decline, comparing men carrying 2 (high-risk) vs 0-1 risk allele (low-risk). Effect modification by HIV suppression status (defined as HIV type 1 RNA level <400 copies/mL for >90% of follow-up time) was evaluated using interaction terms and stratified analyses.
Of the 333 African American men included in this study, 54 (16%) carried the APOL1 high-risk genotype. Among HIV-infected men with unsuppressed viral loads, those with the high-risk genotype had a 2.42 mL/minute/1.73 m(2) (95% confidence interval [CI], -3.52 to -1.32) faster annual eGFR decline than men with the low-risk genotype. This association was independent of age, comorbid conditions, baseline eGFR, ancestry, and HIV-related factors. In contrast, the rate of decline was similar by APOL1 genotype among men with sustained viral suppression (-0.16 mL/minute/1.73 m(2)/year; 95% CI, -.59 to .27; P for interaction <.001).
Unsuppressed HIV-infected African Americans with the APOL1 high-risk genotype experience an accelerated rate of kidney function decline; HIV suppression with antiretroviral therapy may reduce these deleterious renal effects.
现有数据表明,携带两份APOL1风险等位基因的感染人类免疫缺陷病毒(HIV)的非裔美国人患肾病的风险高于非携带者。我们试图确定在多中心艾滋病队列研究中登记的非裔美国人中,HIV RNA抑制是否能减轻APOL1相关的肾功能下降。
我们对感染HIV的男性进行G1和G2风险等位基因及祖先信息标记的基因分型。使用混合效应模型估计估计肾小球滤过率(eGFR)下降的年速率,比较携带两份(高风险)与0 - 1份风险等位基因(低风险)的男性。使用交互项和分层分析评估HIV抑制状态(定义为在超过90%的随访时间内1型HIV RNA水平<400拷贝/mL)的效应修饰。
在本研究纳入的333名非裔美国男性中,54名(16%)携带APOL1高风险基因型。在病毒载量未得到抑制的感染HIV的男性中,高风险基因型者的eGFR年下降速率比低风险基因型者快2.42 mL/分钟/1.73 m²(95%置信区间[CI],-3.52至-1.32)。这种关联独立于年龄、合并症、基线eGFR、祖先和HIV相关因素。相比之下,在病毒载量持续得到抑制的男性中,APOL1基因型之间的下降速率相似(-0.16 mL/分钟/1.73 m²/年;95% CI,-0.59至0.27;交互作用P<0.001)。
APOL1高风险基因型且HIV未得到抑制的感染非裔美国人肾功能下降速率加快;抗逆转录病毒疗法抑制HIV可能减少这些有害的肾脏影响。